CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Hypodermoclysis for Frail Patients and Patients in Long Term Care: Clinical Effectiveness, Cost Effectiveness, and Guidelines

Last updated: July 13, 2020
Project Number: RA1122-000
Product Line: Rapid Response
Research Type: Devices and Systems
Report Type: Reference List
Result type: Report

Question

  1. What is the clinical effectiveness of hypodermoclysis in frail patients who are at risk of dehydration or who are dehydrated in any setting?
  2. What is the clinical effectiveness of hypodermoclysis in geriatric patients who are at risk of dehydration or who are dehydrated in long term care?
  3. What is the cost-effectiveness of hypodermoclysis in frail patients who are at risk of dehydration or who are dehydrated in any setting?
  4. What is the cost-effectiveness of hypodermoclysis in geriatric patients who are at risk of dehydration or who are dehydrated in long term care?
  5. What are the evidence-based guidelines regarding the use of hypodermoclysis in frail patients or patients in long term care?

Key Message

One systematic review and one randomized controlled trial were identified regarding the clinical effectiveness of hypodermoclysis in geriatric patients who are at risk of dehydration or who are dehydrated in long term care. No evidence was identified regarding the clinical effectiveness or cost-effectiveness of hypodermoclysis in frail patients who are at risk of dehydration or who are dehydrated in any setting. No evidence was identified regarding the cost-effectiveness of hypodermoclysis in geriatric patients who are at risk of dehydration or who are dehydrated in long term care. No evidence-based guidelines were identified regarding the use of hypodermoclysis in frail patients or patients in long term care.